Decreased enteric fatty acid amide hydrolase activity is associated with colonic inertia in slow transit constipation

Journal of Gastroenterology and Hepatology (Australia)

Volumn 29, Issue 2, 2014, Pages 276-283

  Zhang, Shu Cheng ^a   Wang, Wei Lin ^a   Su, Peng Jun ^a   Jiang, Kai Lei ^a   Yuan, Zheng Wei ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Clinical gastroenterology in the elderly; Colonic motility and disorders; Enteric neural pathways; Functional disorders

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; CANNABINOID 1 RECEPTOR; ENDOCANNABINOID; FATTY ACID AMIDASE; PALMIDROL; AMIDASE; CNR1 PROTEIN, HUMAN; FATTY-ACID AMIDE HYDROLASE;

ADOLESCENT; ADULT; ARTICLE; CASE STUDY; CHILD; CLINICAL ARTICLE; COLON MOTILITY; CONSTIPATION; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GANGLION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; INTESTINE INNERVATION; LAPAROTOMY; MALE; MYENTERIC PLEXUS; NERVE FIBER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; WESTERN BLOTTING; CLASSIFICATION; CLINICAL GASTROENTEROLOGY IN THE ELDERLY; COLONIC MOTILITY AND DISORDERS; ENTERIC NEURAL PATHWAYS; ENZYMOLOGY; FUNCTIONAL DISORDERS.; GASTROINTESTINAL TRANSIT; GENETICS; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; YOUNG ADULT;

CLINICAL GASTROENTEROLOGY IN THE ELDERLY; COLONIC MOTILITY AND DISORDERS; ENTERIC NEURAL PATHWAYS; FUNCTIONAL DISORDERS.;

ADOLESCENT; ADULT; AMIDOHYDROLASES; CHILD; CONSTIPATION; FEMALE; GASTROINTESTINAL TRANSIT; HUMANS; MALE; MIDDLE AGED; RECEPTOR, CANNABINOID, CB1; YOUNG ADULT;

EID: 84896348672     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12346     Document Type: Article

References (35)

1. Milla P, Cucchiara S, DiLorenzo C etal. Motility disorders in childhood: working group report of the first world congress of pediatric gastroenterology, hepatology, and nutrition. J. Pediatr. Gastroenterol. Nutr. 2002; 35 (Suppl. 2): S187-195.
2. Youssef NN, Di Lorenzo C. Childhood constipation: evaluation and treatment. J. Clin. Gastroenterol. 2001; 33: 199-205.
3. Kamm MA. Constipation and its management. BMJ 2003; 327: 459-460.
4. Maurer AH, Krevsky B. Whole-gut transit scintigraphy in the evaluation of small-bowel and colon transit disorders. Semin. Nucl. Med. 1995; 25: 326-338.
5. Benninga MA, Buller HA, Tytgat GN etal. Colonic transit time in constipated children: does pediatric slow-transit constipation exist? J. Pediatr. Gastroenterol. Nutr. 1996; 23: 241-251.
6. de Lorijn F, van Wijk MP, Reitsma JB etal. Prognosis of constipation: clinical factors and colonic transit time. Arch. Dis. Child. 2004; 89: 723-727.
7. Chitkara DK, Bredenoord AJ, Cremonini F etal. The role of pelvic floor dysfunction and slow colonic transit in adolescents with refractory constipation. Am. J. Gastroenterol. 2004; 99: 1579-1584.
8. Tomita R, Fujisaki S, Ikeda T etal. Role of nitric oxide in the colon of patients with slow-transit constipation. Dis. Colon Rectum 2002; 45: 593-600.
9. King SK, Sutcliffe JR, Ong SY etal. Substance P and vasoactive intestinal peptide are reduced in right transverse colon in pediatric slow-transit constipation. Neurogastroenterol. Motil. 2010; 22: 883-892.
10. Tomita R. Regulation of the peptidergic nerves (substance P and vasoactive intestinal peptide) in the colon of women patients with slow transit constipation: an in vitro study. Hepatogastroenterology 2008; 55: 500-507.
11. Galligan JJ. Cannabinoid signalling in the enteric nervous system. Neurogastroenterol. Motil. 2009; 21: 899-902.
12. Bashashati M, Storr MA, Nikas SP etal. Inhibiting fatty acid amide hydrolase normalizes endotoxin-induced enhanced gastrointestinal motility in mice. Br. J. Pharmacol. 2012; 165: 1556-1571.
13. Hons IM, Storr MA, Mackie K etal. Plasticity of mouse enteric synapses mediated through endocannabinoid and purinergic signaling. Neurogastroenterol. Motil. 2012; 24: e113-124.
14. Capasso R, Matias I, Lutz B etal. Fatty acid amide hydrolase controls mouse intestinal motility in vivo. Gastroenterology 2005; 129: 941-951.
15. Pinto L, Izzo AA, Cascio MG etal. Endocannabinoids as physiological regulators of colonic propulsion in mice. Gastroenterology 2002; 123: 227-234.
16. Abalo R, Vera G, López-Pérez AE etal. The gastrointestinal pharmacology of cannabinoids: focus on motility. Pharmacology 2012; 90: 1-10.
17. Izzo AA, Sharkey KA. Cannabinoids and the gut: new developments and emerging concepts. Pharmacol. Ther. 2010; 126: 21-38.
18. Wong BS, Camilleri M, Busciglio I etal. Pharmacogenetic trial of a cannabinoid agonist shows reduced fasting colonic motility in patients with nonconstipated irritable bowel syndrome. Gastroenterology 2011; 141: 1638-1647.
19. Camilleri M, Katzka DA. Irritable bowel syndrome: methods, mechanisms, and pathophysiology. Genetic epidemiology and pharmacogenetics in irritable bowel syndrome. Am. J. Physiol. Gastrointest. Liver Physiol. 2012; 302: G1075-1084.
20. Labar G, Michaux C. Fatty acid amide hydrolase: from characterization to therapeutics. Chem. Biodivers. 2007; 4: 1882-1902.
21. Yuan Z, Cheng W, Hou A, Wang W etal. Constipation is associated with spina bifida occulta in children. Clin. Gastroenterol. Hepatol. 2008; 6: 1348-1353.
22. Bharucha AE, Low P, Camilleri M etal. A randomised controlled study of the effect of cholinesterase inhibition on colon function in patients with diabetes mellitus and constipation. Gut 2013; 62: 708-715.
23. Qiao L, Chen CS, Zhang SC. Significance of expression of fatty acid amide hydrolase in normal colon wall. World Chinese Journal of Digestology 2009; 17: 7-9.
24. Coutts AA, Pertwee RG. Inhibition by cannabinoid receptor agonists of acetylcholine release from the guinea-pig myenteric plexus. Br. J. Pharmacol. 1997; 121: 1557-1566.
25. Izzo AA, Mascolo N, Tonini M etal. Modulation of peristalsis by cannabinoid CB1 ligands in the isolated guinea pig ileum. Br. J. Pharmacol. 2000; 129: 984-990.
26. Izzo AA, Capasso R, Pinto L etal. Effect of vanilloid drugs on gastrointestinal transit in mice. Br. J. Pharmacol. 2001; 132: 1411-1416.
27. Mang CF, Erbelding D, Kilbinger H. Differential effects of anandamide on acetylcholine release in the guinea-pig ileum mediated via vanilloid and non-CB 1 cannabinoid receptor. Br. J. Pharmacol. 2001; 134: 161-167.
28. Kojima S, Sugiura T, Waku K etal. Contractile response to a cannabimimetic eicosanoid, 2-arachidonoylglycerol, of longitudinal smooth muscle from the guinea-pig distal colon in vitro. Eur. J. Pharmacol. 2002; 444: 203-207.
29. Pertwee RG, Fernando SR, Griffin G etal. Effect of phenylmethylsulphonyl fluoride on the potency of anandamide as an inhibitor of electrically evoked contractions in two isolated tissue preparations. Eur. J. Pharmacol. 1995; 272: 73-78.
30. Katayama K, Ueda N, Kurahashi Y etal. Distribution of anandamide amidohydrolase in rat tissues with special reference to small intestine. Biochim. Biophys. Acta 1997; 1347: 212-218.
31. Chon SH, Douglass JD, Zhou YX etal. Over-expression of monoacylglycerol lipase (MGL) in small intestine alters endocannabinoid levels and whole body energy balance, resulting in obesity. PLoS One 2012; 7: e43962.
32. Camilleri M, Carlson P, McKinzie S etal. Genetic variation in endocannabinoid metabolism, gastrointestinal motility, and sensation. Am. J. Physiol. Gastrointest. Liver Physiol. 2008; 294: G13-19.
33. Hill MN, Kumar SA, Filipski SB etal. Disruption of fatty acid amide hydrolase activity prevents the effects of chronic stress on anxiety and amygdalar microstructure. Mol. Psychiatry 2012 (Jul 10). doi: 10.1038/mp.2012.90
34. Huggins JP, Smart TS, Langman S etal. An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee. Pain 2012; 153: 1837-1846.
35. D'Addario C, Di Francesco A, Arosio B etal. Epigenetic regulation of fatty acid amide hydrolase in Alzheimer disease. PLoS One 2012; 7: e39186.